Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Sarcoma, Synovial 2Rhabdoid Tumor 2Recurrence 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia 1Hepatic Impairment 1Hematologic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

tazemetostat 1capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hepatic Impairment × tazemetostat × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡